Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Trial Profile

A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Encequidar+paclitaxel-Athenex (Primary)
  • Indications Haemangiosarcoma; Skin cancer
  • Focus Therapeutic Use
  • Sponsors Athenex
  • Most Recent Events

    • 15 Oct 2019 Planned number of patients changed from 14 to 25.
    • 03 May 2019 Results from the part 1 of the study were presented in an Athenex media release.
    • 03 May 2019 According to an Athenex media release, till date 10 patients have been enrolled in this study. Based on the preliminary data, the study has met the criteria required to proceed to full enrollment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top